French pharma major Sanofi (Euronext: SAN) revealed this morning that first-quarter 2015 group sales increased 2.4% at constant rates, or 12.3% on a reported basis, to 8.81 billion euros ($9.82 billion, but net profit fell 6% to 1.02 billion euros. Sanofi’s shares dipped 1% to 90.63 euros in mid-morning trading.
Business net income, ie, adjusted income excluding the impact of acquisitions and divestments, increased 12% to 1.73 billion euros, helped by a weaker euro and its Genzyme biotech business, beating analysts’ expected business net income of 1.58 billion euros, according to a poll by The Wall Street Journal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze